已收盤 11-20 16:00:00 美东时间
-0.264
-53.56%
Aprea Therapeutics ( ($APRE) ) has issued an announcement. On November 20, 2026...
11-20 22:31
Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmacokinetics support once-daily administration Planned expansion into focused cohorts in uterine serou...
11-20 22:03
Aprea Therapeutics announced updated results from its Phase 1 trial of APR-1051, a WEE1 inhibitor, showing clinical activity, safety, and pharmacokinetics supporting once-daily dosing. Among 56 patients, two confirmed partial responses were observed in uterine cancers, with durable stable disease in five others. Pharmacodynamic data demonstrated WEE1 target engagement across doses. Aprea plans to expand enrollment in uterine serous carcinoma and ...
11-20 14:00
Aprea Therapeutics' CEO, Oren Gilad, will participate in a fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference on November 9, 2026, at 10:00 am ET in Boston. Interested investors can join via the provided webcast link. Aprea, a precision medicine oncology company, focuses on developing targeted therapies for biomarker-defined cancers, with lead programs APR-1051 and ATRN-119 in clinical development. For more information, vis...
11-05 21:05
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 80.85 percent increase over losses of $(0.47) per share from the same period last year.
11-04 21:36
Aprea Therapeutics reported Q3 2026 financial results with $37.8 million in cash and provided updates on its WEE1 inhibitor APR-1051, which is advancing in a Phase 1 clinical trial expanded to nine sites. The company plans to present interim Phase 1 data at the EORTC-NCI-AACR Symposium in November 2026 and expects to select the dose for Part 2 in early 2027. APR-1051 is being evaluated in biomarker-defined cancers, with a focus on endometrial can...
11-04 13:30
今日重点评级关注:HC Wainwright & Co.:维持Alector"买入"评级,目标价从5美元升至8美元;摩根大通:维持ORIC Pharmaceuticals"超配"评级,目标价从23美元升至26美元
10-15 12:36
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Buy rating and announces Price Target of $2.
10-15 04:52
Abstract accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to take place November 18-20, 2026, in Barcelona, Spain. "We look forward to presenting an update from our ongoing Phase 1 ACESOT-1051 trial at the EORTC-NCI-AACR Sym...
09-22 20:33
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on its existing patent portfolio.
08-28 20:17